Evidence map›Paper›PMID 35342717›Full record

ArticleJournal of clinical & translational endocrinology2022

Characterization of glucose metabolism in youth with vs. without cystic fibrosis liver disease: A pilot study.

Maria Socorro Rayas, Kara S Hughan, Rida Javaid, Andrea Kelly, Marzieh Salehi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & translational endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Maria Socorro RayasDivision of Pediatric Endocrinology and Diabetes, University of Texas Health San Antonio, 7703 Floyd Curl, San Antonio, TX 78229, USA.
Kara S HughanDivision of Pediatric Endocrinology and Diabetes, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Rida JavaidDivision of Pediatric Endocrinology and Diabetes, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Andrea KellyDivision of Pediatric Endocrinology and Diabetes, Children's Hospital of Philadelphia, Perelman School of Medicine of University of Pennsylvania, 2716 South Street, Philadelphia, PA 19146, USA.
Marzieh SalehiDivision of Diabetes, University of Texas Health San Antonio, 7703 Floyd Curl, San Antonio, TX 78229, USA.
Children's Hospital of Pittsburgh · USAudie L. Murphy Memorial VA Hospital · USChildren's Hospital of Philadelphia · USThe University of Texas Health Science Center at San Antonio · US

Funding

VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL A. LAZAR · 1986 to 2026
$48.3M
Institutional Career Development Core (KL2)KL2TR002646 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI TSEVAT, JOEL · 2018 to 2022
$3.4M
The Weight-Independent Effects of Bariatric Surgeries on Islet Cell FunctionR01DK105379 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SALEHI, MARZIEH · 2015 to 2020
$2.4M
NCATS NIH HHS KL2 TR002646NIDDK NIH HHS P30 DK019525NIDDK NIH HHS R01 DK105379
6 · The paper itself

Abstract

Background: Diabetes and liver disease are life-threatening complications of cystic fibrosis (CF). CF-liver disease is a risk factor for CF related diabetes (CFRD) development, but the underlying mechanisms linking the two co-morbidities are not known. The objective of this pilot study was to characterize glucose metabolism in youth with CF with and without liver disease. Methods: In this two-center cross-sectional study, 20 youth with CF with and without liver disease underwent a 3-hour oral glucose tolerance test. Subjects were categorized by liver disease (LD) status [no LD, mild LD, severe LD] and diabetes status. Measures of glucose excursion, islet cell secretory responses, insulin sensitivity and clearance were obtained. Results: Participants with severe LD had the highest fasting, peak, and glucose area under the curve over 3 h (AUC Conclusion: In this small cohort, subjects with severe LD tended to have more impaired glycemia, insulin secretion, insulin sensitivity and clearance. Larger studies are imperative to define the pathogenesis to inform clinical care guidelines in terms of CFRD screening, diagnosis, and treatment options.

Indexed as

APRI, Aspartate aminotransferase to Platelet Ratio IndexCAP, controlled attenuation parameterCFRD, cystic fibrosis related diabetesCystic fibrosisDiabetesDM, diabetesFFA, free fatty acidsFib4, Fibrosis-4GIP, gastric inhibitory polypeptideGLP-1, glucagon like peptide-1Hepatic insulin clearanceHOMA-IR, Homeostatic Model Assessment of Insulin ResistanceInsulin resistancekPa, kilopascalsLD, liver disease, AUC, area under the curveLiver diseaseLSM, liver stiffness measurementOGIS, oral glucose derived insulin sensitivityOGTT, oral glucose tolerance testOral glucose tolerance testVCTE, vibration controlled transient elastography

Identifiers

PMID35342717
PMCPMC8942823
OpenAlexW4220862097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.